



SAFETY DATA SHEET

Revision date: 17-May-2018

Version: 1.1

Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Dopamine Hydrochloride Injection, USP (Hospira Inc.)

Trade Name: Dopamine Hydrochloride Injection, USP

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as cardiovascular drug

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

SAFETY DATA SHEET

Material Name: Dopamine Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-May-2018

Page 2 of 7

Version: 1.1

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Dopamine Hydrochloride	62-31-7	200-527-8	Not Listed	4-8

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Citric acid, anhydrous	77-92-9	201-069-1	Not Listed	*
sodium metabisulphite	8681-57-4	Not Listed	Not Listed	*
Sodium Citrate	6132-04-3	612-118-5	Not Listed	*
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.

Skin Contact:

Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:

Move to fresh air. If discomfort occurs, get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions

None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:

None

5. FIRE FIGHTING MEASURES

Extinguishing Media:

As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products:

Formation of toxic gases is possible during heating or fire. May include oxides of carbon.

Fire / Explosion Hazards:

Not applicable

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

SAFETY DATA SHEET

Material Name: Dopamine Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-May-2018

Page 3 of 7

Version: 1.1

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Dopamine Hydrochloride

Pfizer Occupational Exposure Band (OEB): OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

SAFETY DATA SHEET

Material Name: Dopamine Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-May-2018

Page 4 of 7

Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	Colorless
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility: No data available
Water Solubility: Soluble
pH: 2.5-5.0
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)

Water for Injection

No data available

sodium metabisulphite

No data available

Sodium Citrate

No data available

Citric acid, anhydrous

No data available

Dopamine Hydrochloride

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available

SAFETY DATA SHEET

Material Name: Dopamine Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-May-2018

Page 5 of 7

Version: 1.1

10. STABILITY AND REACTIVITY

Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Known Clinical Effects:	The most common adverse effects seen during clinical use of this drug include headache, nausea, vomiting, shortness of breath (dyspnea), palpitations, chest pain, increased heart rate (tachycardia), decrease in blood pressure (hypotension).

Acute Toxicity: (Species, Route, End Point, Dose)

Citric acid, anhydrous

Rat Oral LD50 3000 mg/kg

Dopamine Hydrochloride

Rat Oral LD50 2859 mg/kg

Mouse Oral LD50 4361mg/kg

Rat Intravenous LD50 4.8mg/kg

Mouse Intravenous LD50 156mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Citric acid, anhydrous

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Dopamine Hydrochloride

14 Day(s) Dog No route specified 4.5 mg/kg/day NOAEL Gastrointestinal System

14 Day(s) Dog No route specified 13.5 mg/kg/day NOAEL Heart

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Dopamine Hydrochloride

Embryo / Fetal Development Rat No route specified 10 mg/kg/day LOAEL Fetotoxicity, Not teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Dopamine Hydrochloride

Bacterial Mutagenicity (Ames) Equivocal

Mouse Lymphoma Assay Positive

In Vivo Micronucleus Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

SAFETY DATA SHEET

Material Name: Dopamine Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-May-2018

Page 6 of 7

Version: 1.1

11. TOXICOLOGICAL INFORMATION

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties have not been investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
--------------------------	---

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Dopamine Hydrochloride	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present

SAFETY DATA SHEET

Material Name: Dopamine Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-May-2018

Page 7 of 7

Version: 1.1

15. REGULATORY INFORMATION

Australia (AICS):	Present
EU EINECS/ELINCS List	200-527-8
Citric acid, anhydrous	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-069-1
sodium metabisulphite	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Sodium Citrate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	612-118-5
Water for Injection	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

16. OTHER INFORMATION

Data Sources:	Pfizer proprietary drug development information. Publicly available toxicity information.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 10 - Stability and Reactivity.
Revision date:	17-May-2018 Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet